文献速递慢性肾脏病肾血管病与高血压

晚期CKD合并房颤:华法林或利伐沙班与阿哌沙班的安全性和有效性比较

Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study.
PubMed 文献 · Am J Kidney Dis · 2023-10-13

该研究基于美国两个全国性索赔数据库,采用倾向评分匹配队列设计,比较华法林或利伐沙班与阿哌沙班在非透析依赖CKD 4/5期合并房颤患者中的安全性和有效性。结果显示,与阿哌沙班相比,华法林和利伐沙班均与更高的主要出血率相关,而全因死亡率和缺血性卒中风险无显著差异。

要点

  • 与阿哌沙班相比,华法林主要出血风险更高(HR 1.85)。
  • 与阿哌沙班相比,利伐沙班主要出血风险更高(HR 1.69)。
  • 华法林和利伐沙班与阿哌沙班相比,缺血性卒中风险无显著差异。

核心结论

  • 在房颤合并晚期CKD患者中,与阿哌沙班相比,利伐沙班和华法林与更高的主要出血率相关,提示阿哌沙班在该高危人群中具有更优的安全性特征。

研究设计与样本

  • 倾向评分匹配队列研究,使用美国Medicare和Optum Clinformatics Data Mart两个全国性索赔数据库,检索2013年1月1日至2022年3月31日期间非瓣膜性房颤合并CKD 4/5期患者,华法林与阿哌沙班匹配队列n=12,488,利伐沙班与阿哌沙班匹配队列n=5,720。

主要发现

  • 与阿哌沙班相比,华法林主要出血风险更高(HR 1.85;95%CI 1.59-2.15),包括主要胃肠道出血(HR 1.86;95%CI 1.53-2.25)和颅内出血(HR 2.15;95%CI 1.42-3.25)。
  • 与阿哌沙班相比,利伐沙班主要出血风险更高(HR 1.69;95%CI 1.33-2.15)。
  • 与阿哌沙班相比,华法林(HR 1.08;95%CI 0.98-1.18)和利伐沙班(HR 0.94;95%CI 0.81-1.10)的全因死亡率相似。
  • 与阿哌沙班相比,华法林(HR 1.14;95%CI 0.83-1.57)和利伐沙班(HR 0.71;95%CI 0.40-1.24)的缺血性卒中风险无统计学显著差异,但置信区间较宽。

临床怎么用

  • 在房颤合并非透析依赖CKD 4/5期患者中,选择抗凝药物时可参考本研究结果:与华法林或利伐沙班相比,阿哌沙班与更低的主要出血风险相关。

局限性

  • 缺血性卒中事件数少。
  • 可能存在残余混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Head-to-head data comparing the effectiveness and safety of oral anticoagulants in patients with atrial fibrillation (AF) and advanced chronic kidney disease (CKD) are lacking. We compared the safety and effectiveness of warfarin or rivaroxaban versus apixaban in patients with AF and non-dialysis-dependent CKD stage 4/5. STUDY DESIGN: Propensity score-matched cohort study. SETTING & PARTICIPANTS: 2 nationwide US claims databases, Medicare and Optum's deidentified Clinformatics Data Mart Database, were searched for the interval from January 1, 2013, through March 31, 2022, for patients with nonvalvular AF and CKD stage 4/5 who initiated warfarin versus apixaban (matched cohort, n=12,488) and rivaroxaban versus apixaban (matched cohort, n = 5,720). EXPOSURES: Warfarin, rivaroxaban, or apixaban. OUTCOMES: Primary outcomes included major bleeding and ischemic stroke. Secondary outcomes included all-cause mortality, major gastrointestinal bleeding, and intracranial bleeding. ANALYTICAL APPROACH: Cox regression was used to estimate HRs, and 1:1 propensity-score matching was used to adjust for 80 potential confounders. RESULTS: Compared with apixaban, warfarin initiation was associated with a higher rate of major bleeding (HR, 1.85; 95% CI, 1.59-2.15), including major gastrointestinal bleeding (1.86; 1.53-2.25) and intracranial bleeding (2.15; 1.42-3.25). Compared with apixaban, rivaroxaban was also associated with a higher rate of major bleeding (1.69; 1.33-2.15). All-cause mortality was similar for warfarin (1.08; 0.98-1.18) and rivaroxaban (0.94; 0.81-1.10) versus apixaban. Furthermore, no statistically significant differences for ischemic stroke were observed for warfarin (1.14; 0.83-1.57) or rivaroxaban (0.71; 0.40-1.24) versus apixaban, but the CIs were wide. Similar results were observed for warfarin versus apixaban in the positive control cohort of patients with CKD stage 3, consistent with randomized trial findings. LIMITATIONS: Few ischemic stroke events, potential residual confounding. CONCLUSIONS: In patients with AF and advanced CKD, rivaroxaban and warfarin were associated with higher rates of major bleeding compared with apixaban, suggesting a superior safety profile for apixaban in this high-risk population. PLAIN-LANGUAGE SUMMARY: Different anticoagulants have been shown to reduce the risk of stroke in patients with atrial fibrillation, such as warfarin and direct oral anticoagulants like apixaban and rivaroxaban. Unfortunately, the large-scale randomized trials that compared direct anticoagulants versus warfarin excluded patients with advanced chronic kidney disease. Therefore, the comparative safety and effectiveness of warfarin, apixaban, and rivaroxaban are uncertain in this population. In this study, we used administrative claims data from the United States to answer this question. We found that warfarin and rivaroxaban were associated with increased risks of major bleeding compared with apixaban. There were few stroke events, with no major differences among the 3 drugs in the risk of stroke. In conclusion, this study suggests that apixaban has a better safety profile than warfarin and rivaroxaban.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Fu EL, Desai RJ, Paik JM, et al. Comparative Safety and Effectiveness of Warfarin or Rivaroxaban Versus Apixaban in Patients With Advanced CKD and Atrial Fibrillation: Nationwide US Cohort Study. Am J Kidney Dis. 2023. PMID: 37839687. doi:10.1053/j.ajkd.2023.08.017

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。